Literature DB >> 31985828

Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols.

Claudia Penna1, Ioanna Andreadou2, Manuela Aragno1, Christophe Beauloye3, Luc Bertrand3,4, Antigone Lazou5, Ines Falcão-Pires6, Robert Bell7, Coert J Zuurbier8, Pasquale Pagliaro1, Derek J Hausenloy7,9,10,11,12.   

Abstract

Diabetic patients are at increased risk of developing coronary artery disease and experience worse clinical outcomes following acute myocardial infarction. Novel therapeutic strategies are required to protect the myocardium against the effects of acute ischaemia-reperfusion injury (IRI). These include one or more brief cycles of non-lethal ischaemia and reperfusion prior to the ischaemic event (ischaemic preconditioning [IPC]) or at the onset of reperfusion (ischaemic postconditioning [IPost]) either to the heart or to extracardiac organs (remote ischaemic conditioning [RIC]). Studies suggest that the diabetic heart is resistant to cardioprotective strategies, although clinical evidence is lacking. We overview the available animal models of diabetes, investigating acute myocardial IRI and cardioprotection, experiments investigating the effects of hyperglycaemia on susceptibility to acute myocardial IRI, the response of the diabetic heart to cardioprotective strategies e.g. IPC, IPost and RIC. Finally we highlight the effects of anti-hyperglycaemic agents on susceptibility to acute myocardial IRI and cardioprotection. LINKED ARTICLES: This article is part of a themed issue on Risk factors, comorbidities, and comedications in cardioprotection. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.23/issuetoc.
© 2020 The British Pharmacological Society.

Entities:  

Mesh:

Year:  2020        PMID: 31985828      PMCID: PMC7680002          DOI: 10.1111/bph.14993

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  158 in total

1.  Ischemic postconditioning during primary percutaneous coronary intervention: the effects of postconditioning on myocardial reperfusion in patients with ST-segment elevation myocardial infarction (POST) randomized trial.

Authors:  Joo-Yong Hahn; Young Bin Song; Eun Kyoung Kim; Cheol Woong Yu; Jang-Whan Bae; Woo-Young Chung; Seung-Hyuk Choi; Jin-Ho Choi; Jang-Ho Bae; Kyung Joo An; Jong-Seon Park; Ju Hyeon Oh; Sang-Wook Kim; Jin-Yong Hwang; Jae Kean Ryu; Hun Sik Park; Do-Sun Lim; Hyeon-Cheol Gwon
Journal:  Circulation       Date:  2013-09-25       Impact factor: 29.690

2.  Hyperglycemia prevents isoflurane-induced preconditioning against myocardial infarction.

Authors:  Franz Kehl; John G Krolikowski; Boris Mraovic; Paul S Pagel; David C Warltier; Judy R Kersten
Journal:  Anesthesiology       Date:  2002-01       Impact factor: 7.892

3.  Effect of metformin pretreatment on myocardial injury during coronary artery bypass surgery in patients without diabetes (MetCAB): a double-blind, randomised controlled trial.

Authors:  Saloua El Messaoudi; Rianne Nederlof; Coert J Zuurbier; Henry A van Swieten; Peter Pickkers; Luc Noyez; Hendrik-Jan Dieker; Marieke J Coenen; A Rogier T Donders; Annemieke Vos; Gerard A Rongen; Niels P Riksen
Journal:  Lancet Diabetes Endocrinol       Date:  2015-07-12       Impact factor: 32.069

4.  Involvement of GSK-3β in attenuation of the cardioprotective effect of ischemic preconditioning in diabetic rat heart.

Authors:  Harlokesh Narayan Yadav; Manjeet Singh; P L Sharma
Journal:  Mol Cell Biochem       Date:  2010-05-30       Impact factor: 3.396

5.  Glucose Fluctuations Aggravate Cardiac Susceptibility to Ischemia/Reperfusion Injury by Modulating MicroRNAs Expression.

Authors:  Shotaro Saito; Luong Cong Thuc; Yasushi Teshima; Chisato Nakada; Satoru Nishio; Hidekazu Kondo; Akira Fukui; Ichitaro Abe; Yuki Ebata; Tetsunori Saikawa; Masatsugu Moriyama; Naohiko Takahashi
Journal:  Circ J       Date:  2015-10-23       Impact factor: 2.993

6.  Myocardial protection by remote ischaemic pre-conditioning is abolished in sulphonylurea-treated diabetics undergoing coronary revascularisation.

Authors:  E Kottenberg; M Thielmann; P Kleinbongard; U H Frey; T Heine; H Jakob; G Heusch; J Peters
Journal:  Acta Anaesthesiol Scand       Date:  2014-02-18       Impact factor: 2.105

7.  15-Deoxy-Delta12,14-prostaglandin J2 and thiazolidinediones transactivate epidermal growth factor and platelet-derived growth factor receptors in vascular smooth muscle cells.

Authors:  Toshihiro Ichiki; Tomotake Tokunou; Kae Fukuyama; Naoko Iino; Satoko Masuda; Akira Takeshita
Journal:  Biochem Biophys Res Commun       Date:  2004-10-15       Impact factor: 3.575

Review 8.  9th Hatter Biannual Meeting: position document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotection.

Authors:  R M Bell; H E Bøtker; R D Carr; S M Davidson; J M Downey; D P Dutka; G Heusch; B Ibanez; R Macallister; C Stoppe; M Ovize; A Redington; J M Walker; D M Yellon
Journal:  Basic Res Cardiol       Date:  2016-05-10       Impact factor: 17.165

Review 9.  An Overview of Murine High Fat Diet as a Model for Type 2 Diabetes Mellitus.

Authors:  Ahlke Heydemann
Journal:  J Diabetes Res       Date:  2016-07-31       Impact factor: 4.011

10.  THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets.

Authors:  Stephen P H Alexander; Eamonn Kelly; Alistair Mathie; John A Peters; Emma L Veale; Jane F Armstrong; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; O Peter Buneman; John A Cidlowski; Arthur Christopoulos; Anthony P Davenport; Doriano Fabbro; Michael Spedding; Jörg Striessnig; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2019-12       Impact factor: 8.739

View more
  18 in total

Review 1.  Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols.

Authors:  Claudia Penna; Ioanna Andreadou; Manuela Aragno; Christophe Beauloye; Luc Bertrand; Antigone Lazou; Ines Falcão-Pires; Robert Bell; Coert J Zuurbier; Pasquale Pagliaro; Derek J Hausenloy
Journal:  Br J Pharmacol       Date:  2020-03-09       Impact factor: 8.739

2.  Risk factors, co-morbidities, and co-medications in cardioprotection: Importance for translation.

Authors:  Rainer Schulz; Ioanna Andreadou; Derek J Hausenloy; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2020-12       Impact factor: 8.739

3.  MG53 E3 Ligase-Dead Mutant Protects Diabetic Hearts From Acute Ischemic/Reperfusion Injury and Ameliorates Diet-Induced Cardiometabolic Damage.

Authors:  Han Feng; Hao Shen; Matthew J Robeson; Yue-Han Wu; Hong-Kun Wu; Geng-Jia Chen; Shuo Zhang; Peng Xie; Li Jin; Yanyun He; Yingfan Wang; Fengxiang Lv; Xinli Hu; Yan Zhang; Rui-Ping Xiao
Journal:  Diabetes       Date:  2022-02-01       Impact factor: 9.461

4.  Alpha-lipoic acid potentiates the anti-arrhythmic effects of ischemic postconditioning in the setting of cardiac ischemia/reperfusion injury in diabetic rats.

Authors:  Sanaz Gholami; Behnaz Mokhtari; Reza Badalzadeh
Journal:  J Diabetes Metab Disord       Date:  2022-03-31

5.  Myocardial salvage by succinate dehydrogenase inhibition in ischemia-reperfusion injury depends on diabetes stage in rats.

Authors:  Pernille Tilma Tonnesen; Marie Vognstoft Hjortbak; Nichlas Riise Jespersen; Thomas Ravn Lassen; Jacob Marthinsen Seefeldt; Hans Erik Bøtker
Journal:  Mol Cell Biochem       Date:  2021-03-05       Impact factor: 3.396

6.  Combination of Cyclosporine A and Levosimendan Induces Cardioprotection under Acute Hyperglycemia.

Authors:  Carolin Torregroza; Birce Yueksel; Raphael Ruske; Martin Stroethoff; Annika Raupach; André Heinen; Markus W Hollmann; Ragnar Huhn; Katharina Feige
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

7.  Mitochondrial shaping proteins as novel treatment targets for cardiomyopathies.

Authors:  Siavash Beikoghli Kalkhoran; Sauri Hernandez-Resendiz; Sang-Ging Ong; Chrishan J A Ramachandra; Derek J Hausenloy
Journal:  Cond Med       Date:  2020-08

Review 8.  Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future.

Authors:  Filipe Ferrari; Rafael S Scheffel; Vítor M Martins; Raul D Santos; Ricardo Stein
Journal:  Am J Cardiovasc Drugs       Date:  2021-12-27       Impact factor: 3.283

9.  Empagliflozin reduces the senescence of cardiac stromal cells and improves cardiac function in a murine model of diabetes.

Authors:  Rosalinda Madonna; Vanessa Doria; Ilaria Minnucci; Angela Pucci; Donato Sante Pierdomenico; Raffaele De Caterina
Journal:  J Cell Mol Med       Date:  2020-09-17       Impact factor: 5.310

10.  Extracellular vesicles - mediating and delivering cardioprotection in acute myocardial infarction and heart failure.

Authors:  Aishwarya Prakash; Gustavo E Crespo-Avilan; Sauri Hernandez-Resendiz; Sang-Ging Ong; Derek J Hausenloy
Journal:  Cond Med       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.